ABSTRACT
Objective: To explore the clinical manifestations, treatment methods, therapeutic efficacy and outcomes of soft tissue osteosarcoma. Methods: The clinical records and follow-up information of 10 patients with soft tissue osteosarcoma admitted in Department of Orthopedics, The Second Affiliated Hospital of Zhejiang University School of Medicine from January 2002 to December 2014 were retrospectively analyzed. Results: Of 10 patients with soft tissue osteosarcoma, six were male, and four were female; 7 patients had tumors located in limbs, and 3 had tumors located in groin, ilium and hip, respectively; 7 tumor lesions were located in superficial layer of deep fascia, and 3 were located in deep layer; concerning tumor size, the tumor diameter was larger than 10 cm in 4 cases , 5-10 cm in 4 cases, and shorter than 5 cm in 2 cases; regarding to pathologic grading, 9 cases were high-grade osteosarcoma, and 1 case was low to medium grade. All patients underwent tumor resection, of which, 4 cases received post-operative chemotherapy, and radiotherapy was not utilized. Three cases suffered from local recurrence, in which, 4 cases also had distant metastasis; no metastasis alone was observed. Four cases died of lung metastasis. Conclusion: Soft tissue osteosarcoma is characterized by low morbidity, high malignant grade, high local recurrence rate and distant metastasis rate, as well as high mortality. Extensive resection is the most important therapeutic strategy for soft tissue osteosarcoma, and its outcomes are related to resection extent and tumor size. Chemotherapy is not a validated treatment strategy, and radiotherapy is also seldom utilized in treatment of soft tissue osteosarcoma.
ABSTRACT
Objective To study the therapeutic effect of hepatic artery and portal vein dual perfusion chemotherapy (AVPC) combined with intratumoral injection of lipiodol-ethanol (ITILE) for unresectable primary hepatic carcinoma (PHC). Methods 138 pathologically proved and unresectable PHC cases were divided into two groups: Group A (80 cases), treated with AVPC through hypodermic implanted drug delivery pumps. Group B (58 cases), treated with AVPC plus ITILE. Results The secondary resection rate was 2.5% in group A, while 12.1% in group B, (P<0.05); The 0.5, 1, 2 years survival rate in group A was 56.3% 45.0% and 21.2%, in group B 81.0% 61.2% and 39.6% respectively. there were significent difference between two groups in 0.5,1,2 years survival rate respectively (P<0.05); the complication occurrence rate was found no significant difference between two groups (P>0.05). Conclusions The therapeutic effect of AVPC plus ITILE for unresectable PHC is much better than that of AVPC alone.